Roche's Anaemia Therapies to Feature Strongly at Upcoming World Congress of Nephrology
Basel, Switzerland (ots/PRNewswire)
Nephrologists attending the upcoming World Congress of Nephrology (WCN) in Rio de Janeiro, Brazil 21-25 April will hear about a wide range of study results from Roche's robust renal anaemia clinical trial programs for its two treatments -- MIRCERA(R) and NeoRecormon(R).
Among the highlights will be two analyses on MIRCERA, Roche's new continuous erythropoietin receptor activator that is awaiting regulatory approval worldwide. The oral and poster presentations review MIRCERA's once monthly haemoglobin stability in the dialysis setting with different patient populations; and new safety data which shows the rate of haemoglobin decline after withholding once monthly MIRCERA treatment.
Eight posters feature results from trials with Roche's first anaemia drug, NeoRecormon. Highlights include further results from the GAIN trial, an observational, prospective study assessing the management of renal anaemia in more than 4,000 haemodialysis patients within everyday clinical practice in 13 European countries; three posters from the IRIDIEM study investigating anaemia management in chronic kidney disease patients with Type 2 diabetes and three posters discussing the preliminary results from the ORAMA study, which used a guideline-based computerized system for clinical decision making.
Details of the study results will be available concurrent with when they are presented at the congress. Please note all information presented at the annual meeting is embargoed for media release until the time of presentation.
Author Abstract Title Presentation Date & Time of Type Presentation MIRCERA Presentations Author: M. Heifets and Hemoglobin (Hb) Poster Sunday, 22 April F. Dougherty Decline After 2007 Withholding C.E.R.A. Administration is not Influenced by C.E.R.A.'s Long Half Life. Author: R. Bernardo C.E.R.A. Administered Oral Monday, 23 April Once Monthly 2007 Maintains Stable Hb Levels in Patients with CKD on Dialysis Regardless of Age and Gender. NeoRecormon Presentations Author: A. Weinreich Effectiveness and Poster Sunday, 22 April safety of haemoglobin 2007 management with epoetin beta - results from the 12-month follow-up period of GAIN. Author: A. Covic Achievement of EBPG Poster Monday, 23 April targets in Eastern 2007 and Western Europe: ORAMA preliminary results. Author: I. MacDougall Does a guideline Poster Monday, 23 April based computerized 2007 clinical decision support system improve Hb attainment? - ORAMA preliminary results. Author: A. Winkler Treatment of renal Poster Monday, 23 April anaemia in clinical 2007 practice taking into account the "European Best Practice Guidelines" (EBPG) supported by a new computer based system (CDS). Author: P. Stevens Cardiovascular Poster Tuesday, 24 comorbidity and April 2007 medicines management in 1154 patients with type 2 diabetes and CKD: The IRIDIEM survey. Author: P. Stevens Anaemia management in Poster Tuesday, 24 1154 patients with April 2007 type 2 DM & CKD: A snapshot of Europe from the IRIDIEM survey. Author: C. Wanner Epidemiology, Poster Tuesday, 24 associated April 2007 comorbidities and treatment management in elderly patients with CKD and type 2 diabetes mellitus. NeoRecormon Presentations Continued Author: P.M. Wee Immediate pain Poster Time - To be sensation is less Announced with s.c. NeoRecormon compared to s.c. Aranesp
Interested journalists may view the meeting schedule online at http://www.wcn2007.org.
For more information, please contact:
Sheila Gies at Roche
Tel: +973-235-4347
Mobile: +973-687-0188
Abenaa Hayes at Weber Shandwick
Tel: +212-445-8337
Mobile: +646-418-7224
Contact:
Sheila Gies at Roche, Tel: +973-235-4347, Mobile: +973-687-0188,
Abenaa Hayes at Weber Shandwick, Tel: +212-445-8337, Mobile:
+646-418-7224